Results 231 to 240 of about 414,323 (331)
When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma. [PDF]
Ratsimbazafy SJN +7 more
europepmc +1 more source
Summary This study provides a comprehensive assessment of haematological malignancies among children, adolescents and young adults aged 0–24 years, using data from the Global Burden of Disease 2021 across 204 countries from 1990 to 2021. We found that global incidence and prevalence remained relatively stable, with approximately 150 000 new cases and ...
Shujuan Xu +4 more
wiley +1 more source
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study. [PDF]
Beksac M +18 more
europepmc +1 more source
Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]
al., et, Vij, Ravi
core +1 more source
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
This systematic review of 55 trials reveals significant inconsistency in defining transplant ineligibility for multiple myeloma. Arbitrary age cut‐offs predominantly drive exclusion, while validated frailty tools and specific comorbidities are frequently underutilized.
Karun Neupane +15 more
wiley +1 more source
Kinetics of MM1.S Multiple Myeloma Cells in a 3D Polymer Particle Culture System with Bone Marrow Stromal Cells and Bortezomib. [PDF]
Aizawa S +7 more
europepmc +1 more source
Super-resolution binding activated localization microscopy through reversible change of DNA conformation [PDF]
Aleksander Szczurek +5 more
core +1 more source
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz +8 more
wiley +1 more source

